Our thoracic team members at the IU Simon Comprehensive Cancer Center are leaders in clinical research. Research led by IU resulted in the FDA approval of both Gemcitabine and Alimta for lung cancer treatment. Other highlights:
- Avastin received FDA approval in lung cancer based on a Phase III trial led by IU.
- Standard of care treatment for both stage III lung cancer and extensive small cell was developed by IU physician-scientists.
- The first study of cetuximab in lung cancer, now approved in Europe, and the first study to demonstrate safety and efficacy of consolidation immunotherapy in lung cancer were completed at IU.
In early 2021, Nasser Hanna, M.D., played a major role in updating guidelines from the world’s leading oncology society, the American Society of Clinical Oncology (ASCO). The guidelines are for physicians who treat non-small lung cancer patients. Hanna led the effort to update the guidelines to include additional treatment options such as immunotherapy.
“These guidelines provide oncologists with a strong evidence based-roadmap to treat the vast majority of patients with non-small cell lung cancer,” he said. Take a listen to this podcast to learn more.
2020 Comprehensive Board Review in Hematology and Medical Oncology: Early Stage and Locally Advanced Non-small Cell Lung Cancer (PDF)
2020 Comprehensive Board Review in Hematology and Medical Oncology: Metastatic Non-Small Cell Lung Cancer (PDF)
Therapy for Stage IV Non-small Cell Lung Cancer with Driver Alterations: ASCO and OH (CCO) Joint Guideline Update: https://www.asco.org/practice-patients/guidelines/thoracic-cancer#/150121
Therapy for Stage IV Non-small Cell Lung Cancer without Driver Alterations: ASCO and OH (CCO) Joint Guideline Update: https://www.asco.org/practice-patients/guidelines/thoracic-cancer#/10201
Lung Cancer Connect videos, collaborative discussions with Dr. HannaPrioritizing Early Diagnosis of Lung Cancer and Challenges During the COVID-19 Pandemic with Dr. Pritchett